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A Missense Mutation in Myelin
Oligodendrocyte Glycoprotein as a Cause
of Familial Narcolepsy with Cataplexy
Hyun Hor,1,8 Luca Bartesaghi,2 Zolta´n Kutalik,2,3 Jose´ L. Vica´rio,4 Clara de Andre´s,5 Corinne Pfister,1
Gert J. Lammers,6 Nicolas Guex,3 Roman Chrast,2 Mehdi Tafti,1,7,9,* and Rosa Peraita-Adrados5,9,*
Narcolepsy is a rare sleep disorder characterized by excessive daytime sleepiness and cataplexy. Familial narcolepsy accounts for less than
10% of all narcolepsy cases. However, documented multiplex families are very rare and causative mutations have not been identified to
date. To identify a causativemutation in familial narcolepsy, we performed linkage analysis in the largest ever reported family, which has
12 affected members, and sequenced coding regions of the genome (exome sequencing) of three affected members with narcolepsy and
cataplexy. We successfully mapped a candidate locus on chromosomal region 6p22.1 (LOD score ¼ 3.85) by linkage analysis. Exome
sequencing identified a missense mutation in the second exon of MOG within the linkage region. A c.398C>G mutation was present
in all affected family members but absent in unaffected members and 775 unrelated control subjects. Transient expression of mutant
myelin oligodendrocyte glycoprotein (MOG) in mouse oligodendrocytes showed abnormal subcellular localization, suggesting an
altered function of the mutant MOG. MOG has recently been linked to various neuropsychiatric disorders and is considered as a key
autoantigen in multiple sclerosis and in its animal model, experimental autoimmune encephalitis. Our finding of a pathogenic MOG
mutation highlights a major role for myelin and oligodendrocytes in narcolepsy and further emphasizes glial involvement in neurode-
generation and neurobehavioral disorders.Narcolepsy (NARCLP1 [MIM 161400]) is a disabling sleep
disorder characterized by irresistible excessive daytime
sleepiness (EDS) and cataplexy, a condition triggered by
strong emotions leading to a sudden loss of muscle
tone.1 Narcolepsy is a rare and mainly sporadic disorder.
Genetic studies revealed a tight association with the HLA
haplotype DRB5*01:01-DRB1*15:01-DQA1*01:02-DQB1*
06:02 (MIM 604305) on chromosome 6 in more than
95% of individuals with narcolepsy with cataplexy.2
This HLA haplotype represents an almost necessary
but not sufficient risk factor for narcolepsy because approx-
imately 20% of the general healthy population carries
the same haplotype. The discovery of hypocretin-1
(HCRT [MIM 602358]) deficiency shed light on the under-
lying pathophysiology of the disease.3 The hypocretin
neurotransmission system, which was identified in the
lateral hypothalamus,4,5 was shown to play a major role
in controlling vigilance states by its diffuse projections
to major wakefulness centers.6 Hypocretin deficiency,
defined as dramatically decreased if not undetectable levels
of hypocretin-1 in the cerebrospinal fluid (CSF), as found
in narcolepsy individuals, is thought to induce an imbal-
ance between waking neurotransmitter systems resulting
in abnormal transitions between vigilance states.3 Because
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recently, circulating TRIB2-specific antibodies reactive
to hypocretin neurons were detected in individuals
with narcolepsy, confirming the autoimmune nature of
narcolepsy.7 Population-based genome-wide association
studies (GWAS) of sporadic narcolepsy in individuals of
European descent also revealed association with variants
in the immune-related genes (TCRA [MIM 186880]
and P2RY11 [MIM 602697]).8,9 However, in contrast to
the well-established HLA contribution (odds ratio > 40),
the identified associations have a small effect size (odds
ratio < 2). We recently suggested a causal involvement of
the HLA class 2 region in the pathogenesis of sporadic
narcolepsy and identified a HLA DQB1 allele (06:03) that
confers a 50-fold increase in protection against narco-
lepsy.10 So far, except in an atypical and unique sporadic
case of narcolepsy that had a mutation in HCRT,11 no
mutation in either hypocretin ligands or receptors has
been reported.
Estimates of prevalence of familial forms of narcolepsy
vary from 1% to 10% but documented multiplex families
are extremely rare (1%–2%).12 Because there are limited
numbers of affected individuals in families, only two
linkage studies are available, and they suggest candidate
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Figure 1. Family Pedigree
Four-generation pedigree of the Spanish
family including the dizygotic twin pair
concordant for narcolepsy-cataplexy in
the third generation; the distribution of
the disorder indicates an autosomal-domi-
nant transmission of the disease-causing
gene. The family consists of 13 (12 living)
family members affected with narcolepsy-
cataplexy. Note that individual III-3 did
not fulfill the full diagnostic criteria
though the clinical characteristics of this
person could not exclude the possibility of
narcolepsy-cataplexy. Seven family mem-
bers were also affected with obesity and
four with type 2 diabetes. Individuals III-5
and III-10 (as well as II-1) were diagnosed
for all three conditions.However, no pathogenic mutation has been identified so
far in any of the reported candidate regions.
We describe here the characterization of a large Spanish
family with 12 affected members diagnosed with narco-
lepsy and cataplexy. We used both genome-wide linkage
analysis and exome capturing with subsequent next-gener-
ation sequencing to identify the causative mutation in this
family.
All participants provided written informed consent and
the study protocol was approved by the ethics committee
of the Gregorio Maran˜o´n University Hospital (Madrid,
Spain). The family was identified through a dizygotic
twin pair concordant for narcolepsy (Figure 1, Table S1,
available online). The twins are part of a four-generation
pedigree that was referred to the Sleep and Epilepsy Unit
of the Department of Clinical Neurophysiology in
Madrid. Both twins as well as all other affected family
members met the diagnostic criteria for narcolepsy and
cataplexy according to the International Classification of
Sleep Disorders.15 The diagnosis was additionally confirmed
by undetectable levels of hypocretin-1 in the cerebrospinal
fluid of both twins. The twin’s mother was diagnosed with
narcolepsy-cataplexy but passed away 10 years ago. One
niece and three of four offspring of the twins are diagnosed
with narcolepsy-cataplexy as well (left branch). Narco-
lepsy-cataplexy is also present in two cousins of the twins
and in four of their offspring (right branch, Table S2).
Fifteen additional family members were interviewed or
investigated in the sleep laboratory and three of them
underwent whole-night polysomnography followed by
a multiple sleep latency test. In 14 of these family
members, narcolepsy was excluded. In one (III-3) narco-
lepsy could not be definitely excluded because EDS
(although without clear cataplexy) was present, but this
person did not completely fulfill the diagnostic criteria
for narcolepsy and her EDS was not improved by contin-
uous positive airway pressure (CPAP) treatment for sleep
apnea. Several family members are obese (or morbidly
obese), and others are suffering from type 2 diabetesThe American(Figure 1). In total, 12 living members of the family are
affected with narcolepsy-cataplexy, seven by obesity, and
four by type 2 diabetes. One of the twins (III-5) and one
of their cousins (III-10) were diagnosed with all three
conditions.
DNA samples of 11 affected and 15 nonaffected family
members were genotyped on Affymetrix Genome-Wide
Human 5.0 SNP arrays. The affected individual IV-19 was
not included in the linkage analysis because this person
was diagnosed very recently. A SNP data set equivalent to
the Affymetrix Mapping 100K genotyping array was ex-
tracted for each individual. With this data set, we per-
formed a parametric linkage analysis by using the Merlin
1.1.2 program.16 Eleven family members were considered
as affected, whereas III-3 was considered as unknown. Para-
metric linkage analysis was performed with a dominant
model, a disease allele frequency of 0.00025, and a 90%
penetrance.
The four-generation pedigree was clearly compatible
with an autosomal-dominant transmission of a gene
responsible for narcolepsy with cataplexy (Figure 1). HLA
genotyping revealed that all affected family members of
the right branch carried the known associated DQB1*
06:02 allele, whereas all affected members of the left
branch carried a different DQB1 allele indicating that
DQB1*06:02 is neither necessary nor sufficient in this
family. Because the dizygotic twins are DQB1*06:02 nega-
tive and the only known mutation was found in HCRT
in a DQB1*06:02 negative individual, we first sequenced
the coding region of HCRT and its two receptors but found
no pathogenic mutation (Table S1). These findings
excluded the HLA class II and the hypocretin system.
Our genome-wide linkage analysis revealed significant
linkage to a region on chromosome 6p22.1-6p22.3, en-
compassing a chromosomal region of 6.08 Mb (3.2 cM)
flanked by the SNPs rs9295612 and rs2517592, with
a maximum LOD score of 3.85 (Figure S1). No additional
loci with suggestive evidence of linkage were detected in
the genome. The linkage region contains 54 genes inJournal of Human Genetics 89, 474–479, September 9, 2011 475
Figure 2. MOG Mutation
Chromatograph example displaying the identified heterozygous
mutation (A) in the second exon ofMOG (C398G) in two affected
(III-5, IV-8) and one healthy family member (III-1). A model of
the Ig-like domain of human p.Ser133Cys MOG mutant (B).
Secondary structure elements are colored from blue (N terminal)
to red (C terminal), and the location of the p.Ser133Cys mutation
is highlighted on the molecular surface in yellow, at the top of
the image. The image was prepared with Swiss-PdbViewer and
rendered with POV-Ray.addition to clusters of butyrophilin, histone, zinc finger,
and olfactory receptors. Because the maximum LOD score
was observed within a region previously linked to reading
disability17 and containing genes with potential function
in the brain, we then sequenced the coding region of
candidate genes GPLD1 (MIM 602515), ALDH5A1 (MIM
610045), KIAA0319 (MIM 609269), TTRAP (MIM
605764), ACOT13, and C6orf62 but did not find any path-
ogenic mutation.
We next performed exome sequencing in three affected
family members (IV-3, IV-12, and IV-5) by means of exome
capturing with the Agilent SureSelect Human All Exon Kit
(38 Mb) according to manufacturer’s protocols. Paired-end
sequencing was performed on an Illumina Genome
Analyzer IIx and the short reads (75 bp) were aligned to
the Human Genome (UCSC hg19) with Bowtie
(v0.12.7).18 Single nucleotide variants (SNVs) were subse-
quently called with SAMTools (v0.1.12). Because narco-
lepsy is a rare disease (general population prevalence ¼
0.025%), known variants according to the SNP databases
of dbSNP (Build 132) and the 1000 Genomes Project
were filtered out with the SeattleSeq’s annotation tool.
This lead to the identification of 148 unknown, heterozy-
gous, and mainly missense SNVs, which were present in
all three exomes (Table S3). Two of those variants were
found on chromosome 6 (in MOG and C4B), but only
one fell into our candidate linkage region. The missense
variant was located in the second exon of MOG (MIM
159465) and represented a C to G substitution (c.398C>G
in NM_206809.3, Figure 2A; nucleotide 29627405 on
chromosome 6, [GRCh37/hg19]) resulting in serine to
cysteine substitution (p.Ser133Cys in Q16653). Sanger
sequencing confirmed the presence of this mutation in
all affected family members. None of the 15 nonaffected
family members carried the mutation. One sister of the476 The American Journal of Human Genetics 89, 474–479, Septembtwins (III-3), in whom the presence of narcolepsy could
not be excluded, also carried the mutation. We next
genotyped the putative mutation in 775 unrelated control
subjects, 370 individuals with sporadic narcolepsy-
cataplexy, and 41 individuals with narcolepsy without
cataplexy. None of them carried the mutation. Similarly,
resequencing of the coding region of MOG (Table S4) in
35 unrelated familial cases revealed, except for known
SNPs, neither the same nor additional causative muta-
tion(s). A search of the 1000 Genomes database identified
many rare variants, but none was considered as pathogenic
(Table S5). These findings strongly suggest that the identi-
fied mutation is unique to our family.
PolyPhen-2 annotating tool19 was then used to predict
the functional effect of the c.398C>G mutation, and
the analysis indicated that the mutation is pathogenic
with the maximum score of 1. We next used Swiss-
PdbViewer20 to align the human MOG (Q16653) onto
the mouse MOG (1PY9 crystal structure) and introduced
the p.Ser133Cys mutation. The analysis revealed that this
residue is located at the tip of the solvent exposed FG-
loop of the Ig-like domain of MOG (Figure 2B), which
has been previously described as a critical epitope region
interacting with the demyelinating monoclonal antibody
8-18C5.21 The Ig-like domain contains two cysteines
(Cys53 and Cys127), which form a disulfide bond charac-
teristic of the Ig-like fold. Because the additional cysteine
present in the p.Ser133Cys mutant is spatially very distant
from either of them in the native fold (over 19 A˚), the crea-
tion of a wrong disulfide bond during protein folding
would result in a misfolded domain. Cysteine misbonding
in the Ig-like domain has been previously reported to result
in the genetic disease hyaline fibromatosis.22 On the other
hand, even if the domain folds correctly, the presence of
a surface-exposed cysteine is likely to result in the forma-
tion of protein dimers or aggregates resulting in a nonfunc-
tional MOG. To assess this possibility, the identified MOG
mutation was introduced in a mammalian expression
vector containing full-length human MOG cDNA
(pcDNA6.2/C-EmGFP-Topo-hMOG, subsequently called
MOG-GFP)23 by means of site-directed in-vitro mutagen-
esis. Both wild-type (MOG-GFP) and mutated vectors
(c.398C>G-MOG-GFP) were transiently transfected in
murine oligodendroglial precursor cells (Oli-neu)24 and
the effect of the mutation on the subcellular localization
of MOG investigated (Figure 3). Cells transfected with
MOG-GFP showed mainly a perinuclear and membrane
localization as previously described.24 In contrast, transfec-
tion with c.398C>G-MOG-GFP revealed an ectopically
clustered localization of the mutated protein in the cyto-
plasm of both the precursor and differentiated cells
although its membrane localization did not seem affected.
These findings support the idea that the c.398C>G muta-
tion must be pathogenic.
The myelin oligodendrocyte protein is a member of the
immunoglobulin superfamily and a minor component of
the myelin sheath in the CNS, where it is exclusivelyer 9, 2011
Figure 3. In Vitro Expression of the Mutant MOG
Localization of wild-type and mutated forms of MOG in Oli-neu
cells. Oli-neu cells kept at nondifferentiated (A and B) or differen-
tiated (C and D) stages were used to localize wild-type (MOG-GFP
[A and C]) or mutated (C398G-MOG-GFP; [B and D]) forms of
myelin oligodendrocyte glycoprotein (MOG: green; nuclear dye
DAPI: blue). Wild-type MOG mainly shows a perinuclear and
membrane localization (A and C). In contrast, the mutated
C398G-MOG-GFP shows ectopically clustered localization in cyto-
plasm although its membrane localization seems to be preserved
(B and D). The scale bar represents 20 mm.expressed at the outmost layer of the myelin sheath as well
as in oligodendrocytes.25 MOG is a target myelin antigen,
and the mature protein has an extracellular IgV-like
domain that contains three encephalitogenic epitopes.
Thus, MOG serves as a target for autoimmune attacks in
CNS-directed immune responses, and its implication in
the pathogenesis ofMS, especially in experimental autoim-
mune encephalomyelitis (EAE), the animal model of MS, is
well established.26 Because young individuals with MS
(who share the same HLA DRB1-DQB1 haplotype as narco-
lepsy), and particularly individuals diagnosed with acute
disseminated encephalomyelitis, display serumMOG anti-
bodies23,27,28 and because our identified mutation is
located in the third encephalitogenic epitope of MOG
(RDHSYQEE epitope), we performed an ELISA test for
MOG antibodies in six affected family members (III-5,
III-6, III-15, IV-3, IV-4, and IV-5) and found no evidence
that the mutation induces autoimmunity against MOG.
Also, TRIB2 antibodies recently reported to target hypocre-
tin neurons7 were not detected in any family members.
Considering the possibility that unknown antibodies tar-
geting hypocretin neurons might play a role in the patho-
genesis of the disease, sections of human hypothalamus
were costained with the sera of affected family members
and an antibody against hypocretin-1. Again, no anti-
bodies were detected in the sera of affected family
members, excluding a potential autoimmune attack target-
ing hypocretin neurons. We also performed a MRI scan of
the brain in two affected family members (III-15, IV-12)The Americanthat revealed no structural lesions, and especially no white
matter lesions in the hypothalamic region. This finding,
together with a lack of clinical symptoms suggestive of
MS, excluded the possibility that the presence of narco-
lepsy is a consequence of MS lesions in the CNS.
Recent studies suggested that myelin and oligoden-
droyctes can play an important role in neuronal signaling
and are also involved in the dopaminergic and glutaminer-
gic circuitry of the brain.29 In this context, myelin and
oligodendrocytes were linked to the pathogenesis of neu-
rodevelopmental disorders such as schizophrenia. Genetic
association studies in neuropsychiatric disorders revealed
evidence for association of myelin and oligodendrocyte-
related genes, such as NRG1 (MIM 142445) and ERBB4
(MIM 600543), with schizophrenia.29 However, causative
mutations in MOG have not been reported and SNVs in
MOG have not been shown to be significantly associated
with MS, schizophrenia, or other neuropsychiatric disor-
ders. Nevertheless, we showed both by structural modeling
and our transfection experiments that the identified muta-
tion leads to an ectopically clustered expression pattern in
the cytoplasm. The observed abnormal pattern of expres-
sionmight result from two nonexclusive possibilities. First,
the mutation changes a serine to cysteine (Ser133Cys), six
amino acids downstream of another cysteine that partici-
pates in the unique disulfuide bond (Cys53-Cys127).30
The presence of this new cysteine might create the wrong
disulfide bond and therefore disrupt the folding and the
stability of the protein. Second, the RDHSYQEE epitope
of MOG, which harbors the identified mutation, is known
to interact with the mouse monoclonal antibody 8-18C5.
Binding of 8-18C5 to MOG on the surface of oligodendro-
cytes leads to microtubule depolymerization in vitro, sug-
gesting a role for MOG in the organization of the cytoskel-
eton that is compromised by binding of 8-18C5.31 The
altered expression pattern we found could be a conse-
quence of an inactivation of the MOG-cytoskeleton inter-
action. Accordingly, mutating Ser133 to Glu was shown to
abolish the binding of 8-18C5 antibody to MOG.21 Alter-
natively, it could also be a consequence of a stronger inter-
action(s) between MOG and its potential interactors. The
identification of such interactors might be one of the
major goals in follow-up studies to identify and explain
the possible link between myelin, oligodendrocytes, and
hypocretin deficiency.
It was previously shown that taiep myelin mutant rats
develop REM sleep abnormalities and cataplexy-like
episodes and share pharmacological alterations similar to
the canine model of narcolepsy; this suggests that abnor-
malities in myelination can lead to a narcolepsy-like
phenotype.32 Interestingly, the phenotype of taiep rats
was linked to microtubule alterations in the cytoplasm of
oligodendrocytes that lead to deficits in myelin membrane
formation.33 In this context it should be noted that MOG
deficient mice (MOG/) have been extensively investi-
gated for CNS-directed immune responses34 but have not
been examined for possible sleep phenotypes. In a pilotJournal of Human Genetics 89, 474–479, September 9, 2011 477
study we have video-recorded four MOG/ mice but did
not observe any cataplexy-like behavior (sleep recordings
in these mice are in progress). The absence of narcolepsy-
like behavior in MOG/ mice further suggests that the
identified mutation might be a dominant-negative muta-
tion (gain of function). Generation of transgenic mice
carrying c.398C>G-MOG will be an appropriate model to
identify a narcolepsy-like phenotype in mice and could
possibly help to find the missing link with hypocretin
deficiency.
Gene expression studies in major depression, bipolar
disorder, schizophrenia, and MS indicates that genes ex-
pressed in oligodendrocytes are downregulated,35 corrobo-
rating the hypothesis that loss of trophic support by
oligodendrocytes might be causal to neurodegeneration
and neurodevelopmental disorders. The identification of
a mutation in MOG, so far unique to our family, not only
provides an insight into pathogenesis of narcolepsy, but
also highlights the role of myelin and oligodendrocytes
in disease susceptibility in other complex neuropsychiatric
disorders.Supplemental Data
Supplemental Data include one figure and five tables and can be
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